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Background: During the last century, mass vaccination programs have achieved considerable success across the
world in immunizing against several serious infectious diseases. However, vaccinations are threatened by their own
success after results have been obtained: the more the incidence of potentially devastating diseases decreases,
thanks to the success of vaccination programs, the more public attention shifts towards real or alleged “side effects”
of vaccines.
Methods: We analyze the experience of 153 children with “reaction to a previous vaccine dose” continuing the
vaccination protocol in the safe environment of the Center for risk vaccination at the Bambino Gesù Children’s
Hospital IRCCS in Rome, from 2009 to 2011.
Results: To assess the suitability for vaccination, a specialized pre-vaccination advice and a skin prick test (SPT) was
undergone, according to Wood’s guideline; 151 children were SPT negative and full vaccine was administered. Of
the 153 children examined just 13 had symptoms suggestive of IgE-mediated reaction-type reactions with
angioedema manifestations. Among them, 2 had positive STP, which required alternative measures of administration
of the vaccine. No cases of post vaccination reaction was reported and no vaccination program was stopped due
to a severe reaction.
Conclusions: Inadequate levels of immunization against infectious diseases remain a significant problem for
public health. However, the reasons for incomplete vaccination and non-adoption of vaccination services are
manifold. To maintain public confidence in vaccines, advanced immunization programs must include activities for
monitoring the safety of the vaccine at the individual level and pursuing specialized counseling pre-and
post-vaccination for those at risk. Our results underlined a gap between true and referred adverse reactions and
are consistent with vaccine safety. Anyway, a continuous assessment of the risks and benefits of vaccination is
required and the results must be disclosed in order to strengthen confidence in the existing and in the new
immunization programs.
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Since the days of Jenner and Pasteur, inducing an immune
response to infectious diseases by the way of vaccination
has become a widely applied intervention to keep people
healthy. Globally, the population coverage of vaccination
programs has expanded so that immunization has served
to eradicate potential fatal diseases, such as smallpox.
Moreover, vaccination has stickling reduced the morbidity
and mortality due to childhood infectious diseases in de-
veloped countries and also protected infants too young to
be vaccinated [1]. Nevertheless, parents may be still
hesitant to get their children vaccinated due to a lack of
knowledge of the seriousness of the disease, skepticism
about the vaccination benefits, and increased fear of ad-
verse events following immunization. In order to imple-
ment vaccination coverage, misinformation regarding
vaccines must be addressed promptly. In particular, to
improve vaccination, healthcare providers should take
advantage of every healthcare visit as an opportunity
to evaluate vaccination status and administer vaccines
when needed [2]. Declining vaccination rates should
facilitate the spread of illness and death from vaccine-
preventable diseases and should increase costs for so-
ciety, both in direct health care costs and indirectly in
lost productivity [3].
Despite currently available vaccines are safe [4,5], mild
adverse reactions are occasionally observed. Severe reac-
tions such as anaphylaxis [6] may occur in rare cases (0,26
case per 1000000 doses).
These are generally due to the components contained in
vaccines such as egg protein, gelatin, antibiotics and other
potential additives, rather than to specific antigens.
The approach to the patient starts with an evaluation
of the symptoms and of the timing of their appearance
from vaccination. The immediate reactions are generally
easier to identify and to attribute to the hypersensitivity
to vaccine for both the timing and the characteristic
symptoms of the allergic reaction. Moreover, being IgE-
mediated, causative agent can be identified by skin prick
tests (SPT) or in vitro by specific IgE assay. Skin tests
and/or search for specific serum IgE are extremely use-
ful for evaluating the patient's risk of relapse: this is be-
cause the reactions to the next dose of the same vaccine
may be more immediate and severe than the first time
and, eventually life threatening [7].
Delayed-type reactions are generally much more difficult
to attribute to a vaccine [8]. Most of the signs and symp-
toms are nonspecific and may be caused by other factors,
including intercurrent infections. Patients should therefore
be carefully evaluated in order to exclude other possible
causes before any conclusion. Since the delayed reactions
are not IgE-mediated, skin tests or in vitro studies are not
useful to identify the causative agent or the responsible
vaccine component.Other laboratory tests are not reliable in the diagnosis
of non-IgE-mediated hypersensitivity reactions. The de-
cisions regarding patients with suspected delayed-type
reaction must be left to the clinical judgment in most
situations. Although non-IgE-mediated delayed reactions
may be important, they rarely put the patient in severe
life-threatening. The occurrence of a delayed vaccine re-
action does not predispose to an immediate reaction to
the next dose.
Delayed reactions occur from hours, up to days after
exposure. The longest possible interval between expos-
ure and the onset of symptoms is not completely clear,
although most immunologists agree that reactions may
occur up to 2 or 3 weeks after exposure. Most delayed re-
actions are classified as type 3 hypersensitivity and due to
the formation of immune complexes, although other less
well-defined mechanisms including T cell-mediated pro-
cesses (type hypersensitivity 4), may also play a role [9].
Therefore, according to World Allergy Organization
classification [10] (WAO), immunological reactions to
drugs (including vaccines) are distinguished according to
the time of onset of symptoms in:
1. immediate reactions that may start from a few
minutes to 1–2 hours after administration of the
vaccine, and are IgE-mediated.
2. delayed reactions that may occur from several hours
up to days after administration. These reactions can
be caused by different mechanisms, but they are
rarely IgE-mediated.
A combination of several signs and symptoms (up to 40)
characterize the immediate reactions (IgE-mediated); the
most common signs and symptoms are:
 Skin symptoms, including hot flashes, itching,
urticaria, angioedema
 Respiratory symptoms, including nasal secretion and
congestion, change in voice quality, sensation of
throat closure or choking, stridor, coughing,
wheezing and dyspnea
 Cardiovascular symptoms, including weakness,
syncope, altered mental status, palpitations,
hypotension.
 Gastrointestinal symptoms, including nausea,
cramps or abdominal pain, diarrhea and dysphagia.
The most severe form of IgE-mediated reaction is ana-
phylaxis, defined as a systemic allergic reaction with rapid
onset and worsening which can lead to the patient's death
[11,12]. Anaphylactic reactions to vaccines are very rare
(0,26 case per 1000000 doses) [6].
Delayed reactions may be of immunological or non-
immunological type [13]. Fever and irritability, local
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the injection site, are common and self-limiting and
should not preclude further doses of vaccine. Other de-
layed reactions include rare cases of erythema nodosum
[14] and encephalopathy; some of these reactions may be
contraindications to further doses of specific vaccines.
Vaccine administration may cause vasovagal reaction
(fainting) in certain patients who are prone to this response.
Vasovagal reactions are characterized by hypotension,
pallor, sweating, weakness, nausea, vomiting, bradycardia,
and if severe, loss of consciousness.
Vasovagal reactions are able to simulate anaphylaxis,
because both can lead to hypotension and collapse [15].
However, fainting is usually preceded by pallor, while
anaphylaxis often begins with hot flashes and may also in-
clude itching, hives and angioedema. In anafilaxis, there is
more often tachycardia than bradycardia.
In patients who reported fainting in response to vaccin-
ation, it is cautious to administer vaccines in supine position.
No action is absolutely risk free. As for associated vac-
cination risks, we must distinguish between real and per-
ceived risks. Differentiation between coincidence and
causality is of utmost importance in this respect. To assert
that a given event is caused by vaccination, it is especially
necessary to rule out other causes that may come to a
diagnosis of exclusion. The timing of symptoms appear-
ance from vaccination is often determinant. Severe allergic
vaccine reactions are very rare and difficult to predict.
To maintain public confidence to vaccines, advanced
immunization programs must include activities for moni-
toring safety of vaccines at the individual level, as well as
pursuing specialized pre-and post-vaccination counseling
for subjects at risk [12,16].
Methods
Since 2004, at the Bambino Gesù Children’s Hospital
IRCCS in Rome, a Centre for risk Immunization is active
as part of the General Pediatrics and Infectious Diseases
Unit, in the Department of Pediatric Medicine.
This center welcomes the growing demand of the Local
Health Agencies of Rome and Lazio and of the pediatricians
and families, to vaccinate children in a “safe environment”
facing a number of challenges and allergy risks; the incom-
ing patients who access to the Centre may have food allergy,
previous reactions to vaccine doses, chronic persistent
asthma, personal history of anaphylaxis, family history of
anaphylaxis, chronic pulmonary, cardiac, renal, neoplastic
pathology who have difficult clinical management, con-
genital and acquired immunodeficiencies and solid organ
transplant recipients receiving immunosuppressive therapy,
candidates for solid organ transplant or bone marrow trans-
plant, splenectomy, requiring personalized vaccination cal-
endars. The conditions of admission to the Centre are both
free demand and prescription by an health care provider.A specialized pre-vaccination advice for all the children
is carried out to assess their suitability for vaccination,
following an anamnestic report; possible solutions to
safely continue vaccinations of children are then pro-
posed to the families, following vaccination programs
tailored to the underlying disease and the reason for
directing the children to the Centre. All this is fully con-
sistent with the absolute, temporary and false contrain-
dications and precautions listed for the individual case.
The data were extrapolated from the retrospective ana-
lysis of discharge records of Day Hospital for risk vaccina-
tion’s hospitalizations. The number of accesses and not
the number of children has initially been reported, as the
same child might have accessed the center several times to
complete the schedule, for different reasons. Among these
reasons, we summarized those sent for “reaction to a pre-
vious vaccine dose”.
Analyzing each case, it was observed that children
were directed to the Center several times for the same
reason and for subsequent different vaccines. The follow-
ing tables will therefore refer to the number of children
and no longer to the reason for access.
The reasons for access were recorded according to re-
ports by parents as very few cases had a report of the Local
Health Agencies, vaccinating physician or pediatrician or a
possible emergency physician; therefore, based on the his-
tory reported by parents, groups were defined according to
a more conventional terminology. No specific and validated
questionnaire has been used to collect data.
Each child was subjected to the procedure provided for
the purpose: skin prick test (SPT) with a full drop of vaccine
in contemporary with histamine SPT as a positive control
and saline as a negative control has been made; if the read-
ing of the SPT is negative, we proceed to the full administra-
tion of the vaccine; if the SPT is positive (positive is
considered a wheal of 3 mm>negative control) and a fur-
ther dose of the vaccine is required, after discussion with the
parents on the risks/benefits budget of vaccination, and after
their consent, we proceed to the administration of the vac-
cine by the method of desensitization, with 3–4 escalating
doses of the vaccine every 15–30 minutes. The child re-
mains under observation for the next 3 hours; authorities
monitor vital parameters prior to vaccination, 30 minutes
after vaccination and after 3 hours [9,17]. Study approval
was provided by the Committee for the Ethical Treatment
of Human Subjects at Bambino Gesù Children’s Hospital.
Written informed consent was obtained from all subjects
or parental/legal guardians before subject enrolment.
Results
938 accesses have been recorded from 2009 to 2011 in
the Center for risk vaccination.
In Table 1 we summarized those sent for “reaction to
a previous vaccine dose”, a total of 286 accesses (30,5%),
Table 1 Accesses and children sent for “reaction to a
previous vaccine dose”





Table 3 Vaccines causing the reaction
Vaccine n° reactions







Diphtheria-tetanus- poliovirus (DTPa) 1
Flu 2
Meningococcus 2
Pentavalent + hepatitis B (HBV) 2
Poliovirus + DTPa 2
Combined pentavalent + HBV + pneumococcus 1
Tetanus 1
Diphtheria-tetanus 1
Hexavalent + MMR 1
Hexavalent + palivizumab 1
Meningococcus + MMR 1
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most 2 times for the same reason and for subsequent dif-
ferent vaccines. Children were 79 males and 74 females.
The average was of 3 years (range 4 months - 16 years);
the median age was of 15 months.
In Table 2 are listed the previous dose of vaccine reac-
tions. In Table 3, we sampled such vaccines causing the re-
action. For 4 children, it has not been possible to trace the
vaccine responsible for the reaction as not noted in the
card discharge.
In Table 4 we classified the reactions caused by admin-
istrations of hexavalent vaccine, its co-administration with
pneumococcus conjugate vaccine, pneumococcal conju-
gate vaccine and measles mumps rubella vaccination
(MMR) vaccine.Table 2 Previous dose of vaccine reactions
Previous dose vaccine reaction n° children
Urticaria 28
Fever and/or hypotonia 20
Anaphylaxis or angioedema 16
Local or generalized edema 15
Convulsions or clonus 12
Fever 12




Uncontrollable crying or irritability 5
Thrombocytopenia 3
Vomiting 3
Fever and vomiting 2
Petechiae at the injection site 2
Hypothermia 1
Local abscess 1
Headache, paresthesia and dyslalia 1
Cyanosis 1
Fever and local petechial 1
Lymphadenopathy 1
Local vasculitis after 8 days 120 children had an underlying disease, including
thrombocytopenia (2), lue connatal (1), atopic dermatitis
(1), chromosomopathy with gastroesophageal reflux dis-
ease (RGE) (1), broncodisplasia (1), RGE (2), renal hy-
poplasia with vesicoureteral reflux (VUR) (2), DiGeorge
syndrom with RGE (1), myoclonic infant epilepsy (1), tuber-
ous sclerosis with West syndrom (1), spherocytosis with
splenectomy (1), mastocytosis (1), asthma (2), cystic fi-
brosis (1), paralysis of the facial nerve (1), milk allergy
(1). The complete list is shown in the Table 5.
Figure 1 shows the algorithm for the management of
an adverse reaction to vaccine.
The hexavalent vaccine was the most reactogenic, al-
most always at the first dose, especially if co-administered
with pneumococcus conjugate vaccine (73%). Numerically
negligible reactions were caused by pneumococcus conju-
gate vaccine alone and MMR vaccine.
SPT were negative in 151 children (98.6%), despite the
reaction to a previous vaccine dose; therefore full vaccine
was administered; there were no reactions within 3 hours
of observation.
Two cases had positive SPT; the first one was a child
who presented 24 hours after first dose of hexavalent,
fever, vomiting and hypotonia and had been redirected to
the center by the Local Health Agencies to continue the
vaccination schedule in a safe environment. This child
came without other vaccines to our observation at the age
of 7 months. After a communicating to his mother the
procedures to undertake in the event of a positive SPT to
hexavalent, she decided to delay the hexavalent, agreeing
Table 4 Reactions caused by vaccines
Type of reaction Type of vaccine
Hexavalent + Pneumococcus Hexavalent Pneumococcus MMR
Urticaria 12 4 3 4
fever and/or hypotonia and/or hyporesponsiveness 11 13 1
Anaphylaxis/Angioedema 6 5 2
Febrile convulsions/Clonus 5 5 1 1
Diffuse erythema 5
Fever ≥ 39 °C 5 5 2




Fever and urticaria 2 6




Vasculitis 8 days later 1
Total 62 50 9 8
Table 5 Reactions in children with underlying disease
Symptoms for access Vaccine causing the reaction Underlying disease
Urticaria Unknown Paralysis of the facial nerve
Lymphadenopathy Unknown Spherocytosis, splenectomy
Urticaria DTPa Mastocytosis
Local swelling Hexavalent Milk allergy
Convulsions Hexavalent Myoclonic epilepsy
Fainting Hexavalent Cystic fibrosis
Respiratory failure Hexavalent Prematurity, broncodisplasia
Thrombocytopenia Hexavalent Thrombocytopenia
Fever and urticaria Hexavalent UVR-renal hypoplasia
Fever and urticaria hexavalent UVR-renal hypoplasia
Fever Hexavalent + pneumococcus Connatal syphilis
Febrile convulsions Hexavalent + pneumococcus Asthma
Vomiting, dyspnea Hexavalent + pneumococcus Genetic disease-RGE
Urticaria Hexavalent + pneumococcus Atopy
Hypotonia Hexavalent + pneumococcus RGE
Fever Hexavalent + pneumococcus RGE
Convulsion 24 hours after Hexavalent + pneumococcus Tuberous sclerosis, West syndrome
Fever and urticaria MMR Asthma
Fever and urticaria Pneumococcus Thrombocytopenia
Uncontrollable crying Pneumococcus DiGeorge syndrome, VSD, RGE
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Figure 1 Algorithm for the management of an adverse reaction to vaccine.
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cine. Due to a referred allergic family history, we decided
to make vaccination at hospital. As the SPT was positive
(wheal 3 mm), we practiced desensitization inoculating
the vaccine in escalating doses, 1/3 of the vial, the first
two subcutaneously, the third intramuscular; after 3 hours
of observation any reaction was registered. Then this child
came back for the second dose of hexavalent. SPT was
negative, so that the vaccine was administered in a single
dose. The child did not manifest any reaction.
The second case presented IgE-mediate sympotms (urti-
caria and angioedema of the trunk and limbs) few minutes
after 2nd dose of hexavalent + pneumococcal conjugate
vaccine, which required access to the emergency room
and treatment with cortisone.
SPT with hexavalent was practiced to the child for the
third dose and resulted positive. After a discussion with
the parents, it was decided not to perform the hexavalent
but to schedule more accesses to safe environment for sin-
gle vaccine separately. All individual SPT were negative,
vaccines administered in full dose in a single solution, no
reaction was recorded within 3 hours of observation.
Of the 153 children examined, whose parents reported
symptoms perceived as severe reaction after vaccination,
only 13 had symptoms suggestive of initial IgE-mediate
sympotms with angioedema manifestations, only 2 of
whom had positive screening a STP, which required
alternative measures of administration of the vaccine. In
none of the 2 cases post vaccination reaction was reported
and the vaccination program was not stopped.Discussion
After an adverse event is recognized as a side effect of
vaccination, assessing its seriousness is the next step.
The profiles on the frequency and severity of side ef-
fects are established for each vaccine in the pre-release
authorization phase and, above all, in the course of
studies of post-release supervision. If deemed neces-
sary, the serious side effects may include termination of
licensure for the vaccine, especially if sufficient to cause an
unfavorable risk-benefit [16].
A post-vaccination correct diagnosis is required for
several reasons. First, if an adverse event is recognized
as a contraindication to further doses of the same or simi-
lar vaccines, misdiagnosis can lead to unjustified cessation
of an immunization series and this places the individual
unnecessarily at increased risk for the vaccine-preventable
disease. Second, without the use of solid, evidence-based
and broadly accepted uniform case definitions, overdiag-
nosis or underdiagnosis of an event may be the result.
This may affect the general perception of the safety profile
of a given vaccine and, in the worst case, can endanger
a whole immunization program. Over-diagnosis obvi-
ously can make a vaccine appear to be more dangerous
than it really is while the opposite may happen with
under-diagnosis. Third, comparability of safety profiles
of vaccines in different studies or surveillance settings
is extremely difficult if not impossible whether differ-
ent case definitions for the same events are being used.
This is especially problematic when rare events are
being studied in meta-analyses [12].
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or for certain risk groups provide moderate to high levels
of individual protection. The magnitude of protection can
be expressed by the percent risk reduction to either de-
velop a specific disease or a specific manifestation of a
disease in comparison to an unimmunized individual
[18]. This can either be performed during pre-licensure
efficacy trials or during outbreaks. Without undisputable
demonstration of its efficacy, a vaccine would neither be
licensed nor recommended by responsible authorities.
If a vaccine is protecting from infection with a micro-
organism that is transmitted from human to human, not
only direct protection of the individual can be expected
but also indirect protection of unimmunised contact
persons can be achieved if immunisation rates are high
enough on a population level. This is the concept of the
so called herd immunity that can be applied to the great
majority of current standard immunisations with the
notable and obvious exception of tetanus, which is not
transmissible between humans [13].
All serious adverse events that occur after the adminis-
tration of a vaccine should be reported to the competent
authorities, even if it is not causal relationship between
an adverse event and the vaccine.
The onset of clinical symptoms after vaccine adminis-
tration not necessarily mean that the origin is always to
be attributed to the vaccine. Most of the side effects of
specific vaccinations turned out to be random observa-
tions. The differentiation between coincidence and causal-
ity is of utmost importance in this regard. The easiest way
to prevent most adverse reactions is to identify during
history taking pre-vaccination, the various precautions
and contraindications.
The Italian National Institute of Health has published,
last update in 2009, the “Guide to the contraindications
to vaccination”, a full and important document easy to
use [19]. The preparation of this fourth edition has been
produced by a working group including more than 40
experts in immunization operating in major institutions
in our Country (vaccination of local health services and
the Regions, National Institute of Health, Ministry of
Health, Cochrane Vaccines Field, universities, etc.). This
guide is an adaptation and extension of that produced
by the U.S. CDC.
The Guide is a reference tool for healthcare profes-
sionals working in the field of vaccinations and is
intended to provide technical support for the proper as-
sessment of contraindications or precautions to the vac-
cine administration. Some symptoms or conditions are
mistakenly considered as true contraindications or situ-
ations that induce an attitude of precaution. These er-
rors can lead to missed opportunities for vaccine
administration, individual and social protection, by
major diseases. Conversely, the administration of thevaccine in the presence of true contraindications or pre-
cautions may increase the risk of serious adverse
reactions.
In our study, symptoms were reported by parents as
they perceived them; an accurate history has allowed to
classify them according to conventional canons. For this
reason, we suggest that a specific and validated question-
naire should be prepared to collect data. In our experi-
ence, we found out a gap between true and reported
adverse reactions. The over-diagnosis of adverse reactions
to vaccines implies an inappropriate use of the hospital
setting by pediatricians, by Local Health Agencies of Rome
and Lazio and by children’s families.
In the cases of anaphylaxis history, a real danger has
never been recorded, and this category was assigned to
those cases of angioedemi with or without giant urticaria,
rarely associated with respiratory manifestations type dys-
pnea, always mild. Seizures were always associated with
post vaccination hyperpyrexia and have proved a poster-
iori isolated (simple febrile seizure). The overtone crisis
and dyspnea were almost always associated with crying.
The term “hyporesponsiveness” included what parents re-
ported as “fainting” but in reality there has never been a
loss of consciousness. The item “hives” also included those
referred to as marbling and erythema spread to the whole
body, not necessarily with appearance of papules on the
skin. The risk/benefit ratio analysis in our patients has al-
ways been in favor of the net benefit of immunization,
despite severe reactions have occurred in rare cases.Conclusions
Inadequate levels of immunization against infectious
diseases remain a significant problem for public health.
However, the reasons for incomplete vaccination and non-
adoption of vaccination services are manifold.
To maintain public confidence in vaccines, advanced
immunization programs must include activities for moni-
toring the safety of the vaccine at the individual level, then
pursuing specialized counseling pre-and post-vaccination
for those at risk [20,21], for a better specific risk/benefit
ratio analysis, despite severe reactions may occur in rare
cases.
A limit of our study is that patients were admitted to
hospital for vaccination due to a self- reported diagnosis
of a previous adverse vaccine reactions. Moreover, we col-
lected anamnestic informations, without using a specific
and validated questionnaire. The most important result is
that we found out a gap between true and reported ad-
verse reactions, which led to an inappropriate use of
the hospital setting.Competing interests
The authors declare that they have no competing interests.
Nicolosi et al. Italian Journal of Pediatrics 2014, 40:31 Page 8 of 8
http://www.ijponline.net/content/40/1/31Authors’ contributions
LN and AC wrote the manuscript; AVittucci, EB, AG and RM contributed to
collect data and carried out the tables; AVillani reviewed the manuscript. All
authors read and approved the final manuscript.
Received: 30 October 2013 Accepted: 18 March 2014
Published: 31 March 2014
References
1. Elena B, Mauro B, Valeria C, Salvatore B, Alberto V: “Infectious diseases and
vaccination strategies: How to protect the “unprotectable”? ISRN Prev
Med 2013, 2013(765354):5.
2. Bozzola E, Bozzola M, Tozzi AE, Nicolosi L, Vittucci A, Villani A: Impact of
health care providers’ advice on vaccine refusal for children with an
acute nervous system infection. Eur J Pediatr 2014. Correspondence
Published online: 2014 Feb 6.
3. Ropeik D: How society should respond to the risk of vaccine rejection.
Hum Vaccin Immunother 2013, 9(8):1815–8.
4. Heininger U: The success of immunization-shovelling its own grave?
Vaccine 2004, 22:2071–2.
5. Guillaume L, Bath PA: A content analysis of mass media sources in
relation to the MMR vaccine scare. Health Inform J 2008, 14:323–34.
6. American Academy of Pediatrics: Active immunization. In Red Book 2006
Report of the Committee on Infectious Diseases. 27th edition. Edited by
Pickering LK, Baker CJ, Long SS, McMillan JA. Elk Grove Village, IL: American
Academy of Pediatrics; 2006:446–448.
7. Ruggeberg JU, Gold MS, Bayas J-M, Blum MD, Bonhoeffer J, Friedlander S,
de Souza BG, Heininger U, Imoukhuede B, Khamesipour A, Erlewyn-
Lajeunesse M, Martin S, Mäkelä M, Nell P, Pool V, Simpson N: Brighton
collaboration anaphylaxis working group. Anaphylaxis: case definition
and guidelines for data collection, analysis, and presentation of
immunization safety data. Vaccine 2007, 25(31):5675–5684.
8. Askenase P: Delayed-type hypersensitivity and cellular immunity. In Allergy
principles and practice. 6th edition. Edited by Adkinson NF, Yunginger JY, Busse
W, Bochner B, Holgate ST, Simons FE. St Louis, MO: Mosby; 2003:425–452.
9. Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, Halsey NA:
Hypersensitivity working group of the clinical immunization safety
assessment (CISA) network. An algorithm for treatment of patients with
hypersensitivity reactions after vaccines. Pediatrics 2008, 122(3):e771–7.
doi:10.1542/peds.2008-1002.
10. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala
C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P,
Williams HC: Revised nomenclature for allergy for global use: report of
the nomenclature review committee of the world allergy organization,
October 2003. J Allergy Clin Immunol 2004, 113(5):832.
11. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA,
Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J,
Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe
DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE,
Thomas S, Wood JP, Decker WW: Second symposium on the definition
and management of anaphylaxis: summary report–second national
institute of allergy and infectious disease/food allergy and anaphylaxis
network symposium. J Allergy Clin Immunol 2006, 117(2):391.
12. Vaccine Safety Datalink Team, Mullooly JP, Thompson RS, Bohlke K, Davis RL,
Marcy SM, Braun MM, De Stefano F, Black SB: Risk of anaphylaxis after
vaccination of children and adolescents. Pediatrics 2003, 112(4):815.
13. Advisory Committee on Immunization Practices (ACIP): General
recommendations on immunization. National center for immunization
and respiratory diseases. MMWR Recomm Rep 2011, 60(2):1.
14. Apisarnthanarak A, Uyeki TM, Miller ER, Mundy LM: Serum sickness-like
reaction associated with inactivated influenza vaccination among Thai
health care personnel: risk factors and outcomes. Clin Infect Dis 2009,
49(1):e18–22.
15. Lieberman PL: Anaphylaxis and anaphylactoid reactions. In Middleton's
allergy principles and practice. 6th edition. Edited by Adkinson NF Jr, Busse
WW, Yunginger JW, et al. St. Louis: Elsevier; 2003:1497.
16. Bines J: Intussusception and rotavirus vaccines. Vaccine 2006, 24:3772–6.
17. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J,
Cox L, Khan D, Lang DM, Oppenheimer J, Portnoy JM, Randolph CR, Schuller
DE, Spector SL, Tilles SA, Wallace D: Adverse reactions to vaccines practice
parameter 2012 update. J Allergy Clin Immunol 2012, 130(1):25–43.18. Anderson RM: The concept of herd immunity and the design of
communitybased immunization programmes. Vaccine 1992, 10:928–35.
19. Gallo G, Mel R, Rota MC: Guida alle controindicazioni alle vaccinazioni.
Rapporti ISTISAN 09/13.
20. La Russa PS, Edwards KM, Dekker CL, Klein NP, Halsey NA, Marchant C,
Baxter R, Engler RJ, Kissner J, Slade BA: Understanding the role of human
variation in vaccine adverse events: the Clinical Immunization Safety
Assessment network. Pediatrics 2011, 127(Suppl 1):S65–73.
21. Zanoni G, Berra P, Lucchi I, Ferro A, O'Flanagan D, Levy-Bruhl D, Salmaso S,
Tridente G: Vaccine adverse event monitoring systems across the European
Union countries: time for unifying efforts. Vaccine 2009, 27:3376–84.
doi:10.1186/1824-7288-40-31
Cite this article as: Nicolosi et al.: Vaccine risk assessment in children
with a referred reaction to a previous vaccine dose: 2009–2011
retrospective report at the Bambino Gesu’ children hospital, Rome, Italy.
Italian Journal of Pediatrics 2014 40:31.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
